Get Acquainted with Imugene’s Deep Product Pipeline

July 08, 2020 04:57 AM SAST | By Team Kalkine Media
 Get Acquainted with Imugene’s Deep Product Pipeline

Summary

  • Backed by an international leadership team with extensive commercialisation expertise in the sector, Imugene has developed a robust product portfolio, comprising four potential drugs.
  • In 2020, Imugene intends to progress with Phase 1 trials of CF33 & PD1-Vaxx and continue enrolling into the open-label Phase 2 trial of HER-Vaxx in the fight against gastric cancer.
  • IMU stock has delivered a robust return of over 60 per cent over the last three months (as on 7th July 2020).

Australian biotech player, Imugene Limited (ASX:IMU) deserves closer attention for marking remarkable progress towards the development of its exclusive product pipeline.

Backed by an international leadership team with extensive commercialisation expertise in the sector, Imugene has developed a robust product portfolio, comprising four potential drugs - VAXinia (CF33), CHECKvacc (CF33 & aPDL1), HER-Vaxx (HER-2) and PD1-Vaxx (PD-1). While HER-Vaxx and PD1-Vaxx are the Company’s B-cell cancer immunotherapies, VAXinia and CHECKvacc are oncolytic viruses directed towards a variety of solid cancers.

This year, Imugene intends to progress with Phase 1 trials of CF33 & PD1-Vaxx and continue enrolling into the open-label Phase 2 trial of HER-Vaxx in the fight against gastric cancer.

CF33’s Constructs - VAXinia and CHECKvacc

Imugene’s chimeric vaccinia (pox) virus, CF33 has been developed by Professor Yuman Fong at Los Angeles-based City of Hope Comprehensive Cancer Center. CF33 includes two additional genes inserted into the virus, hNIS (Human Sodium-Iodide Symporter) gene to facilitate imaging to chase the virus in vivo and mediate targeted radiotherapy, as well as anti PD-L1 to allow enhancement of anti-cancer immunotherapy.

Imugene has both CF33 candidates for development – the armed construct which combines CF33 with PD-L1 inhibition and hNIS (CHECKvacc) and the unarmed construct (VAXinia).

Both CHECKvacc and VAXinia constructs have been shown in pre-clinical studies to shrink injected and distant tumors, not directly targeted but in the metastatic spread. Besides, pre-clinical data has demonstrated that CF33 outperforms Amgen or Genelux oncolytic viruses in cancer growth inhibition.

Imugene is planning to undertake a VAXinia Phase 1 MAST (Mixed Advanced Solid Tumors) study in patients suffering from metastatic solid tumors or selected advanced tumors to evaluate the tolerance and safety of CF33-hNIS, administered intravenously (IV) or intratumorally (IT).

Source: Company’s July 2020 Presentation

Moreover, Imugene has also planned CHECKvacc Phase 1 trial in Triple Negative Breast Cancer (TNBC) patients. It is worth noting that pre-clinical studies undertaken at City of Hope have shown encouraging results in TNBC patients when an immune checkpoint inhibitor (especially a PD-L1 inhibitor) is combined with CF33 to generate CHECKvacc.

PD1-Vaxx

The PD1-Vaxx is Imugene’s second B-cell immunotherapy, which has been designed to treat tumors like lung cancer by interfering with PD1/PD-L1 binding and interaction, and deliver an anti-cancer effect akin to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies.

PD1-Vaxx has shown encouraging responses and efficacy in preclinical studies, with strong inhibition of tumor growth in mouse models of colorectal cancer.

Imugene has planned to carry out Phase 1 clinical trial of PD1-Vaxx in CY2020, targeting NSCLC (non-small cell lung cancer), the most common type of lung cancer accounting for ~80% of cases. The Phase 1 trial involves testing of three different doses to identify safety, immunological data, and preliminary investigation of an optimal Phase 2 dose for the expansion stage of the study. Full study details can also be found on clinical trials.gov under study ID: NCT04432207

Source: Company’s July 2020 Presentation

Must Read! Imugene’s Preclinical New Mimotope Cancer Vaccine Research Published in Prestigious Journal

HER-Vaxx

HER-Vaxx is Imugene’s most advanced B-cell immunotherapy, which is under development for the treatment of HER2+ gastric cancer and holds the potential to treat other HER2-overexpressing cancers. In pre-clinical studies as well as the completed Phase 1b study, HER-Vaxx has been shown to stimulate a potent polyclonal antibody response to HER2/neu receptor.

Imugene’s HER-Vaxx Phase 1b trial returned robust results with no toxicity or safety issues, with all patients demonstrating increased antibody responses. The Company is now progressing with the recruitment of patients in Phase 2 trial being conducted at various sites across Eastern Europe and India.

Imugene has already received a go-ahead from Independent Data Monitoring Committee (IDMC) for the Phase 2 trial, with committee confirming no safety concerns from HER-Vaxx.

Way Ahead

Source: Company’s July 2020 Presentation

IMU traded at $0.035 on 8 July 2020 (11:56 AM AEST).


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

Sponsored Articles


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.